Shares of Merck MRK rose nearly 6% on Friday after the company announced that the EMA’s Committee for Medicinal Products for ...

EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

Shares of Merck & Co. (MRK) rose 5% on Friday after the pharmaceutical giant reported positive developments across multiple ...

The U.S. Food and Drug Administration (FDA) on Friday approved injectable and intravenous versions of Merck’s (MRK) blockbuster anti-PD-1 therapy Keytruda for bladder cancer as part of a combination ...

Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response rates ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...

Merck received a positive opinion from the European Medicines Agency backing approval of its Keytruda-Padcev combination for a subset of bladder patients.

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...

TheFly reported on May 22 that MRK announced that the European Medicines Agency’s Committee for Medicinal Products for Human ...